Molecular Signatures of Cancer Stemness Characterize the Correlations with Prognosis and Immune Landscape and Predict Risk Stratification in Pheochromocytomas and Paragangliomas
Background: Pheochromocytoma and paragangliomas (PPGLs) caused refractory hypertension in clinics. The sustained risk of local or metastatic recurrences or new tumor development prompted more research on diagnosis, prognosis prediction, and immunotherapy. Method: The tumor stemness is closely relate...
Saved in:
| Published in | Bioengineering (Basel) Vol. 12; no. 3; p. 219 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Switzerland
MDPI AG
21.02.2025
MDPI |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2306-5354 2306-5354 |
| DOI | 10.3390/bioengineering12030219 |
Cover
| Abstract | Background: Pheochromocytoma and paragangliomas (PPGLs) caused refractory hypertension in clinics. The sustained risk of local or metastatic recurrences or new tumor development prompted more research on diagnosis, prognosis prediction, and immunotherapy. Method: The tumor stemness is closely related to the heterogeneous growth of tumor, metastasis, and drug-resistance, and mRNA expression-based stemness indices (mRNAsi) could reflect tumor stemness. This was calculated based on OCLR machine learning algorithm and PPGLs patients’ TCGA RNAseq data. The relationship between clinical, molecular, and tumor microenvironment (TME) features and tumor stemness was analyzed through the hub genes that best captured the stem cell characteristics of PPGLs using weighted gene co-expression network analysis (WGCNA), Cox, and LASSO regression analysis. Results: Our study found that metastatic PPGLs had higher mRNAsi scores, suggesting the degree of tumor stemness could affect metastasis and progression. HRAS, CSDE1, NF1, RET, and VHL-mutant subtypes displayed significant difference in stemness expression. Patients were divided into stemness high-score and low-score subtypes. High-score PPGLs displayed the more unfavorable prognosis compared with low-score, associated with their immune-suppressive features, manifested as low macrophages M1 infiltration and downregulated expression of immune checkpoints. Furthermore, from the viewpoint of stemness features, we established a reliable prognostic for PPGLs, which has the highest AUC value (0.908) in the field so far. And this could stratify PPGLs patients into high-risk and low-risk subtypes, showing the significant differences in prognosis, underlying mechanisms correlated with specific molecular alterations, biological processes activation, and TME. Notably, high immune infiltration and tumor neoantigen in low-risk patients and further resulted in more responsive to immunotherapy. Conclusion: We indicated that tumor stemness could act as the potential biomarker for metastasis or prognosis of PPGLs, and integrated multi-data sources, analyzed valuable stemness-related genes, developed and verified a novel stemness scoring system to predict prognosis and guide the choice of treatment strategies. |
|---|---|
| AbstractList | Background: Pheochromocytoma and paragangliomas (PPGLs) caused refractory hypertension in clinics. The sustained risk of local or metastatic recurrences or new tumor development prompted more research on diagnosis, prognosis prediction, and immunotherapy. Method: The tumor stemness is closely related to the heterogeneous growth of tumor, metastasis, and drug-resistance, and mRNA expression-based stemness indices (mRNAsi) could reflect tumor stemness. This was calculated based on OCLR machine learning algorithm and PPGLs patients’ TCGA RNAseq data. The relationship between clinical, molecular, and tumor microenvironment (TME) features and tumor stemness was analyzed through the hub genes that best captured the stem cell characteristics of PPGLs using weighted gene co-expression network analysis (WGCNA), Cox, and LASSO regression analysis. Results: Our study found that metastatic PPGLs had higher mRNAsi scores, suggesting the degree of tumor stemness could affect metastasis and progression. HRAS, CSDE1, NF1, RET, and VHL-mutant subtypes displayed significant difference in stemness expression. Patients were divided into stemness high-score and low-score subtypes. High-score PPGLs displayed the more unfavorable prognosis compared with low-score, associated with their immune-suppressive features, manifested as low macrophages M1 infiltration and downregulated expression of immune checkpoints. Furthermore, from the viewpoint of stemness features, we established a reliable prognostic for PPGLs, which has the highest AUC value (0.908) in the field so far. And this could stratify PPGLs patients into high-risk and low-risk subtypes, showing the significant differences in prognosis, underlying mechanisms correlated with specific molecular alterations, biological processes activation, and TME. Notably, high immune infiltration and tumor neoantigen in low-risk patients and further resulted in more responsive to immunotherapy. Conclusion: We indicated that tumor stemness could act as the potential biomarker for metastasis or prognosis of PPGLs, and integrated multi-data sources, analyzed valuable stemness-related genes, developed and verified a novel stemness scoring system to predict prognosis and guide the choice of treatment strategies. Pheochromocytoma and paragangliomas (PPGLs) caused refractory hypertension in clinics. The sustained risk of local or metastatic recurrences or new tumor development prompted more research on diagnosis, prognosis prediction, and immunotherapy. The tumor stemness is closely related to the heterogeneous growth of tumor, metastasis, and drug-resistance, and mRNA expression-based stemness indices (mRNAsi) could reflect tumor stemness. This was calculated based on OCLR machine learning algorithm and PPGLs patients' TCGA RNAseq data. The relationship between clinical, molecular, and tumor microenvironment (TME) features and tumor stemness was analyzed through the hub genes that best captured the stem cell characteristics of PPGLs using weighted gene co-expression network analysis (WGCNA), Cox, and LASSO regression analysis. Our study found that metastatic PPGLs had higher mRNAsi scores, suggesting the degree of tumor stemness could affect metastasis and progression. , , , , and -mutant subtypes displayed significant difference in stemness expression. Patients were divided into stemness high-score and low-score subtypes. High-score PPGLs displayed the more unfavorable prognosis compared with low-score, associated with their immune-suppressive features, manifested as low macrophages M1 infiltration and downregulated expression of immune checkpoints. Furthermore, from the viewpoint of stemness features, we established a reliable prognostic for PPGLs, which has the highest AUC value (0.908) in the field so far. And this could stratify PPGLs patients into high-risk and low-risk subtypes, showing the significant differences in prognosis, underlying mechanisms correlated with specific molecular alterations, biological processes activation, and TME. Notably, high immune infiltration and tumor neoantigen in low-risk patients and further resulted in more responsive to immunotherapy. We indicated that tumor stemness could act as the potential biomarker for metastasis or prognosis of PPGLs, and integrated multi-data sources, analyzed valuable stemness-related genes, developed and verified a novel stemness scoring system to predict prognosis and guide the choice of treatment strategies. Pheochromocytoma and paragangliomas (PPGLs) caused refractory hypertension in clinics. The sustained risk of local or metastatic recurrences or new tumor development prompted more research on diagnosis, prognosis prediction, and immunotherapy.BACKGROUNDPheochromocytoma and paragangliomas (PPGLs) caused refractory hypertension in clinics. The sustained risk of local or metastatic recurrences or new tumor development prompted more research on diagnosis, prognosis prediction, and immunotherapy.The tumor stemness is closely related to the heterogeneous growth of tumor, metastasis, and drug-resistance, and mRNA expression-based stemness indices (mRNAsi) could reflect tumor stemness. This was calculated based on OCLR machine learning algorithm and PPGLs patients' TCGA RNAseq data. The relationship between clinical, molecular, and tumor microenvironment (TME) features and tumor stemness was analyzed through the hub genes that best captured the stem cell characteristics of PPGLs using weighted gene co-expression network analysis (WGCNA), Cox, and LASSO regression analysis.METHODThe tumor stemness is closely related to the heterogeneous growth of tumor, metastasis, and drug-resistance, and mRNA expression-based stemness indices (mRNAsi) could reflect tumor stemness. This was calculated based on OCLR machine learning algorithm and PPGLs patients' TCGA RNAseq data. The relationship between clinical, molecular, and tumor microenvironment (TME) features and tumor stemness was analyzed through the hub genes that best captured the stem cell characteristics of PPGLs using weighted gene co-expression network analysis (WGCNA), Cox, and LASSO regression analysis.Our study found that metastatic PPGLs had higher mRNAsi scores, suggesting the degree of tumor stemness could affect metastasis and progression. HRAS, CSDE1, NF1, RET, and VHL-mutant subtypes displayed significant difference in stemness expression. Patients were divided into stemness high-score and low-score subtypes. High-score PPGLs displayed the more unfavorable prognosis compared with low-score, associated with their immune-suppressive features, manifested as low macrophages M1 infiltration and downregulated expression of immune checkpoints. Furthermore, from the viewpoint of stemness features, we established a reliable prognostic for PPGLs, which has the highest AUC value (0.908) in the field so far. And this could stratify PPGLs patients into high-risk and low-risk subtypes, showing the significant differences in prognosis, underlying mechanisms correlated with specific molecular alterations, biological processes activation, and TME. Notably, high immune infiltration and tumor neoantigen in low-risk patients and further resulted in more responsive to immunotherapy.RESULTSOur study found that metastatic PPGLs had higher mRNAsi scores, suggesting the degree of tumor stemness could affect metastasis and progression. HRAS, CSDE1, NF1, RET, and VHL-mutant subtypes displayed significant difference in stemness expression. Patients were divided into stemness high-score and low-score subtypes. High-score PPGLs displayed the more unfavorable prognosis compared with low-score, associated with their immune-suppressive features, manifested as low macrophages M1 infiltration and downregulated expression of immune checkpoints. Furthermore, from the viewpoint of stemness features, we established a reliable prognostic for PPGLs, which has the highest AUC value (0.908) in the field so far. And this could stratify PPGLs patients into high-risk and low-risk subtypes, showing the significant differences in prognosis, underlying mechanisms correlated with specific molecular alterations, biological processes activation, and TME. Notably, high immune infiltration and tumor neoantigen in low-risk patients and further resulted in more responsive to immunotherapy.We indicated that tumor stemness could act as the potential biomarker for metastasis or prognosis of PPGLs, and integrated multi-data sources, analyzed valuable stemness-related genes, developed and verified a novel stemness scoring system to predict prognosis and guide the choice of treatment strategies.CONCLUSIONWe indicated that tumor stemness could act as the potential biomarker for metastasis or prognosis of PPGLs, and integrated multi-data sources, analyzed valuable stemness-related genes, developed and verified a novel stemness scoring system to predict prognosis and guide the choice of treatment strategies. |
| Audience | Academic |
| Author | Qiu, Ling Liu, Shuangyu Guo, Zeqi Zhang, Yue Li, Yue Li, Lei Tang, Yueming |
| AuthorAffiliation | 2 Department of Clinical Laboratories, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710004, China; liushuangyuyu@126.com (S.L.); sxycgzq@126.com (Z.G.); 18317009638@163.com (Y.Z.) 1 Department of Laboratory Medicine, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, Beijing 100730, China; lilei30@pumch.cn (L.L.); tangyuem1@126.com (Y.T.) 3 State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, Beijing 100730, China |
| AuthorAffiliation_xml | – name: 2 Department of Clinical Laboratories, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710004, China; liushuangyuyu@126.com (S.L.); sxycgzq@126.com (Z.G.); 18317009638@163.com (Y.Z.) – name: 3 State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, Beijing 100730, China – name: 1 Department of Laboratory Medicine, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, Beijing 100730, China; lilei30@pumch.cn (L.L.); tangyuem1@126.com (Y.T.) |
| Author_xml | – sequence: 1 givenname: Lei surname: Li fullname: Li, Lei – sequence: 2 givenname: Shuangyu surname: Liu fullname: Liu, Shuangyu – sequence: 3 givenname: Zeqi surname: Guo fullname: Guo, Zeqi – sequence: 4 givenname: Yueming surname: Tang fullname: Tang, Yueming – sequence: 5 givenname: Yue surname: Zhang fullname: Zhang, Yue – sequence: 6 givenname: Ling orcidid: 0000-0002-0734-8144 surname: Qiu fullname: Qiu, Ling – sequence: 7 givenname: Yue orcidid: 0000-0002-1129-4572 surname: Li fullname: Li, Yue |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40150683$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkl1v0zAUhiM0xMbYX5gsccNNhz_yeYWmakClIio-rq0T5zhxSexiJ0zlX_EPcdsxVrQLFCmx3rzvc3yO_Tw5sc5iklwyeiVERV_XxqFtjUX0xraMU0E5q54kZ1zQfJaJLD15sD5NLkJYU0qZ4BnP02fJaUpZRvNSnCW_Prge1dSDJ59Na2GcPAbiNJmDVRjFEQeLIZB5Bx7UGCv-RDJ2SObOe-xhNM4GcmvGjqy8a60LJhCwDVkMw2SRLOM6KNjgXlx5bIwayScTvkW2j3Ft1B5CjCWrDp3qvBuc2o5ugANpFSu3YNve7KQXyVMNfcCLu-958vXtzZf5-9ny47vF_Ho5UxnPxvjOOUtVwdOmzoumyFnFFVSoSyGgEILF_mka58EFKMGVzosKKE810KrUeS3Ok8WB2zhYy403A_itdGDkXnC-leBHo3qURa5Q61KLKmepFqJuOACjKFIomKp3rOLAmuwGtrfQ9_dARuXuTOXjZxqTbw7JzVQP2Ci0cWj90XaO_1jTydb9kCyG43ZYJLy6I3j3fcIwysEEhX0PFt0UpGAlT0vKWBatL_-xrt3kbZzyzsVEHGkl_rpaiL0bq10srHZQeV0KXpa8qtLounrEFZ8GB6PifdYm6keBy4ed3rf4565GQ34wKO9C8Kj_d4a_ASCgBj0 |
| Cites_doi | 10.3389/fimmu.2024.1478922 10.1186/s13073-019-0638-6 10.3390/cancers17010066 10.1007/s12022-021-09675-0 10.1186/s13059-017-1349-1 10.1186/s12943-018-0858-1 10.3389/fimmu.2022.796606 10.1007/s12022-022-09704-6 10.1158/0008-5472.CAN-18-0689 10.1210/jc.2018-01968 10.1038/nature25501 10.1186/s13046-018-0978-x 10.3390/ijms22137239 10.1158/0008-5472.CAN-17-0307 10.1038/nmeth.3337 10.3390/genes13060993 10.3390/cancers14030467 10.1002/jcp.27740 10.1186/s12967-023-04683-6 10.1016/j.omto.2022.10.005 10.1016/j.ccell.2017.01.001 10.1210/clinem/dgaa982 10.3390/jcm10010088 10.1016/j.semcancer.2018.06.006 10.1097/MPA.0b013e3181ebb4f0 10.1210/jc.2014-1498 10.1182/bloodadvances.2018015685 10.1186/s13073-014-0095-1 10.1002/jcb.27646 10.3390/cancers14040917 10.1016/j.cell.2018.03.034 10.1007/978-1-0716-0327-7_17 10.1155/2016/9012369 10.1038/s41392-021-00484-9 10.1016/j.ccell.2023.09.011 10.3389/fonc.2023.1139990 10.1186/s13059-016-1070-5 10.1038/s41591-018-0136-1 10.1530/ERC-21-0392 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2025 MDPI AG 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2025 by the authors. 2025 |
| Copyright_xml | – notice: COPYRIGHT 2025 MDPI AG – notice: 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2025 by the authors. 2025 |
| DBID | AAYXX CITATION NPM 8FE 8FG 8FH ABJCF ABUWG AFKRA AZQEC BBNVY BENPR BGLVJ BHPHI CCPQU DWQXO GNUQQ HCIFZ L6V LK8 M7P M7S PHGZM PHGZT PIMPY PKEHL PQEST PQGLB PQQKQ PQUKI PRINS PTHSS 7X8 5PM ADTOC UNPAY DOA |
| DOI | 10.3390/bioengineering12030219 |
| DatabaseName | CrossRef PubMed ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Journals Materials Science & Engineering Collection ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials - QC Biological Science Collection ProQuest Central ProQuest Technology Collection (LUT) Natural Science Collection ProQuest One ProQuest Central ProQuest Central Student SciTech Premium Collection (Proquest) ProQuest Engineering Collection Biological Sciences Biological science database Engineering Database (Proquest) ProQuest Central Premium ProQuest One Academic Publicly Available Content Database (Proquest) ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Engineering Collection MEDLINE - Academic PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest Central Student Technology Collection ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Engineering Collection Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest Central (New) Engineering Collection Engineering Database ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Technology Collection Biological Science Database ProQuest SciTech Collection ProQuest One Academic UKI Edition Materials Science & Engineering Collection ProQuest One Academic ProQuest One Academic (New) MEDLINE - Academic |
| DatabaseTitleList | CrossRef Publicly Available Content Database PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository – sequence: 4 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Engineering |
| EISSN | 2306-5354 |
| ExternalDocumentID | oai_doaj_org_article_76ceff8f39614f33bd2aa10e34a71cbb 10.3390/bioengineering12030219 PMC11939611 A832882994 40150683 10_3390_bioengineering12030219 |
| Genre | Journal Article |
| GroupedDBID | 53G 5VS 8FE 8FG 8FH AAFWJ AAYXX ABDBF ABJCF ACUHS ADBBV AFKRA AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BBNVY BCNDV BENPR BGLVJ BHPHI CCPQU CITATION GROUPED_DOAJ HCIFZ HYE IAO IHR INH ITC KQ8 L6V LK8 M7P M7S MODMG M~E OK1 PGMZT PHGZM PHGZT PIMPY PQGLB PROAC PTHSS RPM NPM ABUWG AZQEC DWQXO GNUQQ PKEHL PQEST PQQKQ PQUKI PRINS 7X8 PUEGO 5PM ADTOC IPNFZ RIG UNPAY |
| ID | FETCH-LOGICAL-c525t-c56214c724db67d76192ca9ef833a73310680452623ac32cf679a024fa098f6b3 |
| IEDL.DBID | DOA |
| ISSN | 2306-5354 |
| IngestDate | Fri Oct 03 12:51:02 EDT 2025 Sun Oct 26 03:23:45 EDT 2025 Tue Sep 30 17:04:51 EDT 2025 Fri Sep 05 17:53:39 EDT 2025 Fri Jul 25 11:49:46 EDT 2025 Mon Oct 20 22:45:04 EDT 2025 Mon Oct 20 16:54:39 EDT 2025 Tue Apr 01 01:21:43 EDT 2025 Thu Oct 16 04:43:45 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | pheochromocytoma and paragangliomas tumor microenvironment prognostic model tumor stemness |
| Language | English |
| License | Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). cc-by |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c525t-c56214c724db67d76192ca9ef833a73310680452623ac32cf679a024fa098f6b3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-0734-8144 0000-0002-1129-4572 |
| OpenAccessLink | https://doaj.org/article/76ceff8f39614f33bd2aa10e34a71cbb |
| PMID | 40150683 |
| PQID | 3181356293 |
| PQPubID | 2055440 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_76ceff8f39614f33bd2aa10e34a71cbb unpaywall_primary_10_3390_bioengineering12030219 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11939611 proquest_miscellaneous_3182480115 proquest_journals_3181356293 gale_infotracmisc_A832882994 gale_infotracacademiconefile_A832882994 pubmed_primary_40150683 crossref_primary_10_3390_bioengineering12030219 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-02-21 |
| PublicationDateYYYYMMDD | 2025-02-21 |
| PublicationDate_xml | – month: 02 year: 2025 text: 2025-02-21 day: 21 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland – name: Basel |
| PublicationTitle | Bioengineering (Basel) |
| PublicationTitleAlternate | Bioengineering (Basel) |
| PublicationYear | 2025 |
| Publisher | MDPI AG MDPI |
| Publisher_xml | – name: MDPI AG – name: MDPI |
| References | Malta (ref_9) 2018; 173 Sainz (ref_40) 2016; 2016 Newman (ref_11) 2015; 12 Racle (ref_12) 2020; 2120 Granberg (ref_26) 2021; 106 Luo (ref_29) 2018; 2 ref_13 Fishbein (ref_8) 2017; 31 ref_34 Finotello (ref_14) 2019; 11 ref_33 ref_32 ref_30 Marquardt (ref_22) 2018; 53 Najafi (ref_28) 2019; 120 Najafi (ref_23) 2019; 234 ref_39 ref_15 ref_37 Cheng (ref_10) 2014; 6 Paino (ref_24) 2018; 37 Xiang (ref_31) 2021; 6 Mete (ref_2) 2022; 33 Chen (ref_4) 2010; 39 Chen (ref_6) 2022; 2022 Ren (ref_27) 2018; 17 Zhou (ref_36) 2022; 27 Jiang (ref_18) 2018; 24 Perez (ref_20) 2022; 29 Xu (ref_17) 2018; 78 Zheng (ref_35) 2023; 21 ref_1 Mariathasan (ref_19) 2018; 554 Hescot (ref_21) 2019; 104 Liu (ref_38) 2023; 41 Li (ref_16) 2017; 77 ref_5 Lenders (ref_3) 2014; 99 ref_7 Juhlin (ref_25) 2021; 32 |
| References_xml | – ident: ref_37 doi: 10.3389/fimmu.2024.1478922 – volume: 11 start-page: 34 year: 2019 ident: ref_14 article-title: Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data publication-title: Genome Med. doi: 10.1186/s13073-019-0638-6 – ident: ref_30 doi: 10.3390/cancers17010066 – volume: 32 start-page: 228 year: 2021 ident: ref_25 article-title: Challenges in Paragangliomas and Pheochromocytomas: From Histology to Molecular Immunohistochemistry publication-title: Endocr. Pathol. doi: 10.1007/s12022-021-09675-0 – ident: ref_13 doi: 10.1186/s13059-017-1349-1 – volume: 2022 start-page: 5694033 year: 2022 ident: ref_6 article-title: Analysis of Stemness and Prognosis of Subtypes in Breast Cancer Using the Transcriptome Sequencing Data publication-title: J. Oncol. – volume: 17 start-page: 108 year: 2018 ident: ref_27 article-title: Tumor microenvironment participates in metastasis of pancreatic cancer publication-title: Mol. Cancer doi: 10.1186/s12943-018-0858-1 – ident: ref_5 doi: 10.3389/fimmu.2022.796606 – volume: 33 start-page: 90 year: 2022 ident: ref_2 article-title: Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas publication-title: Endocr. Pathol. doi: 10.1007/s12022-022-09704-6 – volume: 78 start-page: 6575 year: 2018 ident: ref_17 article-title: TIP: A Web Server for Resolving Tumor Immunophenotype Profiling publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-18-0689 – volume: 104 start-page: 2367 year: 2019 ident: ref_21 article-title: Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study publication-title: J. Clin. Endocrinol. Metab. doi: 10.1210/jc.2018-01968 – volume: 554 start-page: 544 year: 2018 ident: ref_19 article-title: TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells publication-title: Nature doi: 10.1038/nature25501 – volume: 37 start-page: 296 year: 2018 ident: ref_24 article-title: HDAC2 depletion promotes osteosarcoma’s stemness both in vitro and in vivo: A study on a putative new target for CSCs directed therapy publication-title: J. Exp. Clin. Cancer Res. doi: 10.1186/s13046-018-0978-x – ident: ref_32 doi: 10.3390/ijms22137239 – volume: 77 start-page: e108 year: 2017 ident: ref_16 article-title: TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-17-0307 – volume: 12 start-page: 453 year: 2015 ident: ref_11 article-title: Robust enumeration of cell subsets from tissue expression profiles publication-title: Nat. Methods doi: 10.1038/nmeth.3337 – ident: ref_7 doi: 10.3390/genes13060993 – ident: ref_33 doi: 10.3390/cancers14030467 – volume: 234 start-page: 8381 year: 2019 ident: ref_23 article-title: Cancer stem cells (CSCs) in cancer progression and therapy publication-title: J. Cell. Physiol. doi: 10.1002/jcp.27740 – volume: 21 start-page: 789 year: 2023 ident: ref_35 article-title: Integrative multi-omics analysis unveils stemness-associated molecular subtypes in prostate cancer and pan-cancer: Prognostic and therapeutic significance publication-title: J. Transl. Med. doi: 10.1186/s12967-023-04683-6 – volume: 27 start-page: 167 year: 2022 ident: ref_36 article-title: Cancer stem/progenitor signatures refine the classification of clear cell renal cell carcinoma with stratified prognosis and decreased immunotherapy efficacy publication-title: Mol. Ther. Oncolytics doi: 10.1016/j.omto.2022.10.005 – volume: 31 start-page: 181 year: 2017 ident: ref_8 article-title: Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma publication-title: Cancer Cell doi: 10.1016/j.ccell.2017.01.001 – volume: 106 start-page: e1937 year: 2021 ident: ref_26 article-title: Metastatic Pheochromocytomas and Abdominal Paragangliomas publication-title: J. Clin. Endocrinol. Metab. doi: 10.1210/clinem/dgaa982 – ident: ref_34 doi: 10.3390/jcm10010088 – volume: 53 start-page: 90 year: 2018 ident: ref_22 article-title: Emerging functional markers for cancer stem cell-based therapies: Understanding signaling networks for targeting metastasis publication-title: Semin. Cancer Biol. doi: 10.1016/j.semcancer.2018.06.006 – volume: 39 start-page: 775 year: 2010 ident: ref_4 article-title: The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: Pheochromocytoma, paraganglioma, and medullary thyroid cancer publication-title: Pancreas doi: 10.1097/MPA.0b013e3181ebb4f0 – volume: 99 start-page: 1915 year: 2014 ident: ref_3 article-title: Pheochromocytoma and paraganglioma: An endocrine society clinical practice guideline publication-title: J. Clin. Endocrinol. Metab. doi: 10.1210/jc.2014-1498 – volume: 2 start-page: 859 year: 2018 ident: ref_29 article-title: M1 and M2 macrophages differentially regulate hematopoietic stem cell self-renewal and ex vivo expansion publication-title: Blood Adv. doi: 10.1182/bloodadvances.2018015685 – volume: 6 start-page: 540 year: 2014 ident: ref_10 article-title: Systematic evaluation of connectivity map for disease indications publication-title: Genome Med. doi: 10.1186/s13073-014-0095-1 – volume: 120 start-page: 2756 year: 2019 ident: ref_28 article-title: Macrophage polarity in cancer: A review publication-title: J. Cell. Biochem. doi: 10.1002/jcb.27646 – ident: ref_1 doi: 10.3390/cancers14040917 – volume: 173 start-page: 338 year: 2018 ident: ref_9 article-title: Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation publication-title: Cell doi: 10.1016/j.cell.2018.03.034 – volume: 2120 start-page: 233 year: 2020 ident: ref_12 article-title: EPIC: A Tool to Estimate the Proportions of Different Cell Types from Bulk Gene Expression Data publication-title: Methods Mol. Biol. doi: 10.1007/978-1-0716-0327-7_17 – volume: 2016 start-page: 9012369 year: 2016 ident: ref_40 article-title: Cancer Stem Cells and Macrophages: Implications in Tumor Biology and Therapeutic Strategies publication-title: Mediat. Inflamm. doi: 10.1155/2016/9012369 – volume: 6 start-page: 75 year: 2021 ident: ref_31 article-title: Targeting tumor-associated macrophages to synergize tumor immunotherapy publication-title: Signal Transduct. Target. Ther. doi: 10.1038/s41392-021-00484-9 – volume: 41 start-page: 1852 year: 2023 ident: ref_38 article-title: Progenitor-like exhausted SPRY1+CD8+ T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma publication-title: Cancer Cell doi: 10.1016/j.ccell.2023.09.011 – ident: ref_39 doi: 10.3389/fonc.2023.1139990 – ident: ref_15 doi: 10.1186/s13059-016-1070-5 – volume: 24 start-page: 1550 year: 2018 ident: ref_18 article-title: Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response publication-title: Nat. Med. doi: 10.1038/s41591-018-0136-1 – volume: 29 start-page: 533 year: 2022 ident: ref_20 article-title: SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma publication-title: Endocr. Relat. Cancer doi: 10.1530/ERC-21-0392 |
| SSID | ssj0001325264 |
| Score | 2.285859 |
| Snippet | Background: Pheochromocytoma and paragangliomas (PPGLs) caused refractory hypertension in clinics. The sustained risk of local or metastatic recurrences or new... Pheochromocytoma and paragangliomas (PPGLs) caused refractory hypertension in clinics. The sustained risk of local or metastatic recurrences or new tumor... |
| SourceID | doaj unpaywall pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 219 |
| SubjectTerms | Algorithms Biological activity Biomarkers Cancer Cancer therapies Correlation analysis Data mining Development and progression Drug resistance Gene expression Genes Hypertension Immune checkpoint Immunity (Disease) Immunology Immunotherapy Infiltration Lymphocytes Machine learning Macrophages Medical prognosis Metastases Metastasis Mutation Neoantigens Network analysis Paraganglioma Patients Pheochromocytoma pheochromocytoma and paragangliomas Prognosis prognostic model Regression analysis Risk Risk groups RNA RNA sequencing Standard scores Stem cells Survival analysis Tumor antigens Tumor microenvironment tumor stemness Tumors |
| SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwED-N7gF4QHyOwEBGQuKpamLn8wGhrdo0EKuqwaS9RY5jtxEjKW0qNP4r_kPunKRtACFe-uCPJo7Pd2f77vcDeI1erkTPIRmGdLfui8ynS0KbKxMqtGA8sCBJ55Pw7NL_cBVc7cGky4WhsMpOJ1pFnVeKzshHKHueQGOdiHeLb0NijaLb1Y5CQ7bUCvlbCzF2C_Y5IWMNYP_4ZDK92J66CB6gC9CkCgvc74-yotJb5D-Po9Bzgt3ZsVIWzP9Plb1js36Pp7y9Lhfy5ru8vt4xVqf34V7rZbKjRiwewJ4uH8LdHezBR_DzvCPGZZ-KWYPvuWKVYWOSAyys9VdSg2y8gXT-oRm6i2xMhB5tCB2jc1w2XVYUr1esmCxz9p5STjT7SEnEFF5lC6dLuhGq2UWx-sIsJC7FKNk_YUXJpnNdqTmFBqqbmkKWmk745JmkRGMqegyXpyefx2fDlr9hqAIe1Pgbcs9XEffzLIxyOjDhSibaxEJI4ook3g-iOOdCKsGVCaNEos9gpJvEJszEExiUVamfAjNengQ8D9xMSV_mXEqpY1eHLtdBGOvYgVE3X-migelIcXtDM5z-fYYdOKZp3bQmmG1bUC1nabtq0yhU2pjYiAS9GCNERk_2XC18GXkqyxx4Q0KRkjLAL6dkm9OAL02wWukR6kvcwiSJ78BhryUuYtWv7sQqbZXIKt2KvAOvNtXUkwLjSl2tbRtOCEBe4MBBI4WbIfkWPjLG3nFPPntj7teUxdxCjHvo1-OYPQfcjSj_54d99u-hPIc7nCiUCRXAO4RBvVzrF-jX1dnLdrH-AgU_Uss priority: 102 providerName: ProQuest – databaseName: Unpaywall dbid: UNPAY link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELdQ9wA8ML7JGMhISDx1S_yV5LFUTAOxUQGVxlNkO84abSRTmwpt_xX_IXdOWpqB0Hjpg-1rcvb5fBff_Y6Q12DlarAc0qHCu3XBjcBLQp8royycYEx6kKSjY3U4FR9O5EnnKGIuzMb9PQd3fN-UtfsNzBcxkEmGKJ9bSoLtPSBb0-PJ6JuvIAeuseRStGnA_yDunUAeqP9PdbxxHl2Plby9rC705Q99fr5xEB1sk08rFtr4k7O9ZWP27NU1dMeb83if3OtsUjpqhegBueWqh-TuBlLhI_LzaFVGl34pT1s00AWtCzpGqYHGxn1HpUnHawDoK0fBuKRjLP_RBdxR_OpLJ_Mao_vKBdVVTt9jgoqjHzHlGIOxfONkjvdHDf1cLs6oB9DFiCb_J7Ss6GTmajvDQEJ72WCAU0sETz7VmJaMTY_J9ODd1_HhsKv2MLSSyQZ-FYuEjZnIjYpz_LzCrE5dkXCusbIkVgnBguiMa8uZLVScarAwCh2mSaEMf0IGVV25Z4QWUZ5KlsvQWC10zrTWLgmdCpmTKnFJQPZXEpBdtKAeGThDuBjZ3xcjIG9RUNajEZTbN8A6Zt0ez2JlXVEkBU_B5ik4N_jkKHRc6DiyxgTkDYpZhqoDZs7qLgMCXhpBuLIRaFdweNJUBGS3NxK2vO13rwQ161TOIgPlHHGYw5QH5NW6GykxjK5y9dKPYYgXFMmAPG3les2S8GCTCVAnPYnv8dzvqcqZBySPwAsAnqOAhOvNccOJ3fl_kufkDsMizIgrEO2SQTNfuhdgGTbmZacOfgGbimcU priority: 102 providerName: Unpaywall |
| Title | Molecular Signatures of Cancer Stemness Characterize the Correlations with Prognosis and Immune Landscape and Predict Risk Stratification in Pheochromocytomas and Paragangliomas |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/40150683 https://www.proquest.com/docview/3181356293 https://www.proquest.com/docview/3182480115 https://pubmed.ncbi.nlm.nih.gov/PMC11939611 https://doi.org/10.3390/bioengineering12030219 https://doaj.org/article/76ceff8f39614f33bd2aa10e34a71cbb |
| UnpaywallVersion | publishedVersion |
| Volume | 12 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 2306-5354 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001325264 issn: 2306-5354 databaseCode: KQ8 dateStart: 20140101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2306-5354 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001325264 issn: 2306-5354 databaseCode: DOA dateStart: 20140101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVEBS databaseName: EBSCOhost Academic Search Ultimate customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn eissn: 2306-5354 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001325264 issn: 2306-5354 databaseCode: ABDBF dateStart: 20180301 isFulltext: true titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn providerName: EBSCOhost – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2306-5354 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001325264 issn: 2306-5354 databaseCode: M~E dateStart: 20140101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 2306-5354 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001325264 issn: 2306-5354 databaseCode: RPM dateStart: 20150101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 2306-5354 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001325264 issn: 2306-5354 databaseCode: BENPR dateStart: 20140301 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Technology Collection customDbUrl: eissn: 2306-5354 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001325264 issn: 2306-5354 databaseCode: 8FG dateStart: 20140301 isFulltext: true titleUrlDefault: https://search.proquest.com/technologycollection1 providerName: ProQuest |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELZgOQAHxJvAUhkJiVPVxM7Lx7ZsWRBbRQuVllPkOPY2YklWbSq0_Cv-ITNOGhJAggOXRvWjjT3jmbE98w0hL8HKlWA5iHGId-s-z3y8JLSxMqECDcYCC5J0sgyPV_67s-Csl-oLfcIaeOBm4iZRqLQxseECFInhPMuZlJ6ruS8jT2UZSl83Fr3NlD1d4SwAVd-EBHPY10-yotI_Ef48BszNEF6np40saP_vormnm371m7y5Ky_l1Vd5cdFTSou75E5rTdJpM4p75Jou75PbPYzBB-T7yT4BLv1QnDc4nltaGTpHekNhrb-guKPzDrr5m6ZgFtI5Ju5oXeUontfSZFOhX16xpbLM6VsMLdH0PQYLoxuVLUw2ePNT09Ni-5la6Fv0RbI_QouSJmtdqTW6AKqrGl2Tmk7wz-cSA4qx6CFZLY4-zo_HbZ6GsQpYUMNnyDxfRczPszDK8WCEKSm0iTmXmBMS83tgKnPGpeJMmTASEmwDI10RmzDjj8hBWZX6CaHGy0XA8sDNlPQlklrq2NWhy3QQxjp2yGRPr_SygeNIYRuDFE7_TGGHzJCsXWuE07YFwGRpy2Tp35jMIa-QKVJc9DBzSraxC_DSCJ-VTkEuwlZFCN8hh4OWsFjVsHrPVmkrLLYpiFWPwxwK7pAXXTX2RAe4Ulc724Yh0o8XOORxw4XdkHwLExlD73jAn4MxD2vKYm2hxD2w32HMnkPcjpX_cWKf_o-JfUZuMUyojBgB3iE5qDc7_RysvDobkevx4s2I3JjOXs8W8JwdLZPTkV3m8G21TKaffgCb7FuU |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF6V9lA4IN4YCiwSiFMUe3ft2IcKtaFVQpMoKq3Um1mv14nV1g6Joyr8K_4Av42ZtZ0HIMSllxz2YWc9s_PYnfmGkHdg5UqwHIKGh3frgkcCLwlNroynQIMx14Ak9Qde51x8vnAvtsjPOhcGwyprmWgEdZwrPCNvAu85HJR1wD9OvjWwahTertYlNGRVWiHeNxBjVWLHiV7cgAs32-9-Anq_Z-z46KzdaVRVBhrKZW4Bvx5zhGoxEUdeK0a3nikZ6MTnXGJFQ6xOgYW4GZeKM5V4rUCCZkukHfiJF3F47h2yI7gIwPnbOTwaDE9XpzycwUxRpiZzHtjNKM31CmnQYbDJGML8rGlFUzzgTxWxpiN_j9_cnWcTubiRV1dryvH4AblfWbX0oGTDh2RLZ4_IvTWsw8fkR78uxEu_pKMST3RG84S2ke-gsdDXKHZpewkh_V1TME9pGwuIVCF7FM-N6XCaY3xgOqMyi2kXU1w07WHSMoZzmcbhFG-gCnqazi6pgeDFmCjzEJpmdDjWuRpjKKJaFBgiVU6CN48kJjZj0xNyfiuUfEq2szzTzwlNnDhwWezakZJCxkxKqX1bezbTrudr3yLNml7hpIQFCcGdQgqHf6ewRQ6RrMvRCOttGvLpKKykRNjylE4SP-EBWE0J5xG-2bE1F7LlqCiyyAdkihCFD3w5JascCvjTCOMVHoB8BpcpCIRF9jZGgtBQm901W4WV0JqFqy1mkbfLbpyJgXiZzudmDEPEIce1yLOSC5dLEgau0ofZ_gZ_bqx5sydLxwbS3AE_AtbsWMResvJ_ftgX_17KG7LbOev3wl53cPKS3GVYvhkRCZw9sl1M5_oV2JRF9LrauJR8vW1Z8QvsDY2l |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lj9MwEB4ti8TjgHgTWMBIIE5VEzvPA0JLl7JlH6qAlfYWHMdpI5aktKlW5V9x5dcx4yR9AEJc9tKDH0mdGc_DnvkG4DlauRIth6jj0926KxKXLglNroyvUINxz4AkHR37-yfu-1PvdAt-trkwFFbZykQjqNNS0Rl5F3nPEaisI9HNmrCI4V7_9eRbhypI0U1rW06jZpEDvThH9232arCHtH7Bef_tp95-p6kw0FEe9yr89bnjqoC7aeIHKbn0XMlIZ6EQkqoZUmUKKsLNhVSCq8wPIolaLZN2FGZ-IvC5l-ByQCjulKXef7c63xEc57l1UrIQkd1N8lKvMAYdjtuLE8DPmj40ZQP-VA5r2vH3yM2r82IiF-fy7GxNLfZvwo3GnmW7NQPegi1d3IbrayiHd-DHUVuCl33MRzWS6IyVGesRx2Fjpb-SwGW9JXj0d83QMGU9Kh3SBOsxOjFmw2lJkYH5jMkiZQNKbtHskNKVKZDLNA6ndPdUsQ_57Asz4LsUDWUewvKCDce6VGMKQlSLioKj6kn45pGklGZqugsnF0LHe7BdlIV-ACxz0sjjqWcnSroy5VJKHdrat7n2_FCHFnRbesWTGhAkRkeKKBz_ncIWvCGyLkcToLdpKKejuJEPceArnWVhJiK0lzIhEnqzY2vhysBRSWLBS2KKmMQOfjklm-wJ_NME4BXvomRGZymKXAt2NkaiuFCb3S1bxY24msWrzWXBs2U3zaQQvEKXczOGE9aQ41lwv-bC5ZJcA1QZ4uxwgz831rzZU-RjA2buoAeBa3YssJes_J8f9uG_l_IUrqCEiA8HxweP4Bqnus0EReDswHY1nevHaExWyROzaxl8vmgx8QsmZIs_ |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELdQ9wA8ML7JGMhISDx1S_yV5LFUTAOxUQGVxlNkO84abSRTmwpt_xX_IXdOWpqB0Hjpg-1rcvb5fBff_Y6Q12DlarAc0qHCu3XBjcBLQp8royycYEx6kKSjY3U4FR9O5EnnKGIuzMb9PQd3fN-UtfsNzBcxkEmGKJ9bSoLtPSBb0-PJ6JuvIAeuseRStGnA_yDunUAeqP9PdbxxHl2Plby9rC705Q99fr5xEB1sk08rFtr4k7O9ZWP27NU1dMeb83if3OtsUjpqhegBueWqh-TuBlLhI_LzaFVGl34pT1s00AWtCzpGqYHGxn1HpUnHawDoK0fBuKRjLP_RBdxR_OpLJ_Mao_vKBdVVTt9jgoqjHzHlGIOxfONkjvdHDf1cLs6oB9DFiCb_J7Ss6GTmajvDQEJ72WCAU0sETz7VmJaMTY_J9ODd1_HhsKv2MLSSyQZ-FYuEjZnIjYpz_LzCrE5dkXCusbIkVgnBguiMa8uZLVScarAwCh2mSaEMf0IGVV25Z4QWUZ5KlsvQWC10zrTWLgmdCpmTKnFJQPZXEpBdtKAeGThDuBjZ3xcjIG9RUNajEZTbN8A6Zt0ez2JlXVEkBU_B5ik4N_jkKHRc6DiyxgTkDYpZhqoDZs7qLgMCXhpBuLIRaFdweNJUBGS3NxK2vO13rwQ161TOIgPlHHGYw5QH5NW6GykxjK5y9dKPYYgXFMmAPG3les2S8GCTCVAnPYnv8dzvqcqZBySPwAsAnqOAhOvNccOJ3fl_kufkDsMizIgrEO2SQTNfuhdgGTbmZacOfgGbimcU |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Molecular+Signatures+of+Cancer+Stemness+Characterize+the+Correlations+with+Prognosis+and+Immune+Landscape+and+Predict+Risk+Stratification+in+Pheochromocytomas+and+Paragangliomas&rft.jtitle=Bioengineering+%28Basel%29&rft.au=Li%2C+Lei&rft.au=Liu%2C+Shuangyu&rft.au=Guo%2C+Zeqi&rft.au=Tang%2C+Yueming&rft.date=2025-02-21&rft.issn=2306-5354&rft.eissn=2306-5354&rft.volume=12&rft.issue=3&rft.spage=219&rft_id=info:doi/10.3390%2Fbioengineering12030219&rft.externalDBID=n%2Fa&rft.externalDocID=10_3390_bioengineering12030219 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2306-5354&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2306-5354&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2306-5354&client=summon |